The Lung Cancer SPORE Biostatistics and Informatics Core provides support in the areas of biostatistics, clinical informatics, and bioinformatics to SPORE investigators. This consultative and collaborative support is designed to increase the speed and efficiency with which lung cancer research is translated from the lab to the clinic. The Core is designed to provide support in study design, data management, data analysis, clinical informatics system creation, bioinformatics data management and interpretation. The Biostatistics group assists primarily with study and protocol design, and data analysis and interpretation. The Informatics group assists with data quality control, data sharing, designing and maintaining the SPORE database that captures clinical, pathologic, and laboratory data into a relational database. This group also designed the barcode system for collection and storage of all samples. The Bioinformatics group assists with computational evaluations of large databases, especially those created with genomic and proteomic analysis using gene expression and SNP arrays and proteomic profiles. All Core members participate in preparation of reports, presentations, and manuscripts. In addition to these services, Core members will continue their efforts to develop new approaches to improve the efficiency and outcomes of the process of translational research. Biostatistics and Informatics Core members will assist SPORE investigators in the following areas: 1. Experimental design. Design of both pre-clinical and clinical experiments that can provide useful answers to scientific questions of importance in lung cancer. 2. Data collection/storage/retrieval/sharing: Creation and maintenance of a sound and user-friendly infrastructure for data collection, storage, quality assurance, retrieval, and sharing in support of SPORE trials and tissue banking. 3. Data analysis and manuscript preparation: Structuring of data analyses to provide clear answers to questions, and to communicate those findings in reports and papers. 4. Translational research methodology: Development and implementation of coherent methods that improve the efficiency and effectiveness of research across the wide spectrum from pre-clinical research to clinical studies, including work in the development of better understanding of the causes of lung cancer, early detection of lung cancer, biomarkers of lung cancer risk, and lung cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-18W1
Application #
8719579
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
18
Fiscal Year
2013
Total Cost
$123,330
Indirect Cost
$43,315
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Symonds, Jennifer M; Ohm, Angela M; Tan, Aik-Choon et al. (2016) PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells. Oncotarget 7:17905-19
Dziadziuszko, Rafal; Le, Anh T; Wrona, Anna et al. (2016) An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol 11:1273-81
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Scarborough, Hannah A; Helfrich, Barbara A; Casas-Selves, Matias et al. (2016) AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin Cancer Res :
Poczobutt, Joanna M; Nguyen, Teresa T; Hanson, Dwight et al. (2016) Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. J Immunol 196:891-901
Li, Bob T; Ross, Dara S; Aisner, Dara L et al. (2016) HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol 11:414-9
Yoshida, Takeshi; Song, Lanxi; Bai, Yun et al. (2016) ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One 11:e0147344
Ariyawutyakorn, Witthawat; Saichaemchan, Siriwimon; Varella-Garcia, Marileila (2016) Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer 7:633-49
Bunn Jr, Paul A; Minna, John D; Augustyn, Alexander et al. (2016) Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 11:453-74
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322

Showing the most recent 10 out of 350 publications